Prescription
The Prescription division sells and markets medicines which are prescribed by medical practitioners and dispensed against a prescription. The division markets a range of quality and affordable generic medicines, including a portfolio of anti-retroviral medicines.The division enjoys the third position1 in the market based on value and the second position based on volume and has a 8.8% share of prescriptions2.
 |
 |
1 IMS MAT June 2016, including MNC
2 Impact Rx June 2016, including MNC
OVERVIEW
The division has three broad areas:
| Generics | Ethical | |||
 |
The generic portfolio is the largest by value in the Prescription division. External data shows that Adcock Ingram is the 4th ranked generic manufacturer in the prescription market with a share of 8.6% and is growing ahead of the market. Genpayne is the leading brand in the portfolio. The performance of the ARV portfolio, particularly in the private sector, is very encouraging. With a market share of 12,1%, the ARV portfolio is growing at 54%. Trivenz, the triple combination, is the most significant growth contributor. |
The branded portfolio is performing strongly with value growth of 11.8%, ahead of the market growth of 5.5%. | ||
| Strategic Alliances | ||||
| Strategic alliances with multinational companies (MNC) are an important part of the Prescription business. Despite high levels of genericisation, this portfolio continues to grow steadily. |
The portfolios of products are grouped according to therapeutic areas in order to facilitate promotion to relevant specialities:
| TOP TEN BRANDS | BUSINESS FOCUS | MARKET TRENDS | ||||||||||||||||||||||||||||||||||||||||
|
|
|